Semaglutide is linked to a small but significantly elevated risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to the results of a new study.

The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side effects. Historically, semaglutide, the active ingredient in Ozempic and Wegovy, has been administered via weekly injections into the fatty tissue just under the skin of the stomach, thigh or upper arm.